Status: Recruiting
Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)
This open-label extension study will evaluate the long-term safety, tolerability and efficacy of orally inhaled seralutinib in subjects who have completed a previous seralutinib study
Participants needed: 330
Trial details
Phase: Phase 3Age: 18-75Biological sex: AllType: InterventionalSponsor: Gossamer Bio USA, Inc.Updated: Jul 29, 2026Locations: 120
Eligibility criteria
Subjects must have completed a qualifying last visit in a prior seralutinib PAH... [+5]
Severe acute or chronic medical or laboratory abnormality that may increase the... [+1]